Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts.1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie, rivaroxaban, apixaban, edoxaban, and betrixaban) and
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie,
Direct Oral Anticoagulant Use: A Practical Guide to Common
irect oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the preven- tion of thrombosis in several cardiovascular contexts.1
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOACs have emerged a
Management of Anticoagulation Therapy - American Society
Several anticoagulant options are available including vitamin K-antagonists (VKAs) such as warfarin, and direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban. Each anticoag-ulant medication has unique dosing and monitoring requirements that can be
- What are direct oral anticoagulants?
- Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for prevention and treatment of several cardiovascular conditions.
- What are direct oral anticoagulants (DOACs)?
- 3 Center for Preventive Cardiology Knight Cardiovascular Institute Oregon Health & Science University Portland OR. Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist.
- Are direct oral anticoagulants a good alternative to vitamin K antagonist?
- ABSTRACT: Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long- standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular con-ditions.
- Should DOACs be considered as first-line anticoagulant therapy for stroke prevention?
- To this regard, recent practice guidelines recommend that DOACs should be considered as first-line anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF).
- Can a patient transition from anticoagulants to DOAC therapy?
- As with any high‐risk medication such as anticoagulants, clinical situations may arise that require transitioning to or off of DOAC therapy. Two common transition scenarios include (1) switching between anticoagulants and (2) periprocedural management.
- Does rapid onset of a DOAC reduce the risk of subtherapeutic anticoagulation?
- nefit as medication-compliant patients. Conversely, the rapid onset of the DOACs does ensure therapeutic anticoagulation as soon as the DOAC dose is taken, theoretically minimizing the w ndow of subtherapeutic anticoagulation. These considerations should be weighed with the potential risk
